News BriaCell Therapeutics Corp.

Stocks

BCT

CA1079303071

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 09:42:48 2026-07-31 EDT			5-day change	1st Jan Change
4.940 ^CAD	-3.14%		-1.79%	-49.59%

07-16	BriaCell Opens First Canadian Site For Phase 3 Metastatic Breast Cancer Study	MT
07-16	BriaCell Therapeutics Corp. Opens First Canadian Site For Pivotal Phase 3 Trial In Metastatic Breast Cancer	CI

All News

Mentions Relevance

07-16	BriaCell Opens First Canadian Site For Phase 3 Metastatic Breast Cancer Study	MT
07-16	BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT	AQ
07-16	BriaCell Therapeutics Corp. Opens First Canadian Site For Pivotal Phase 3 Trial In Metastatic Breast Cancer	CI
07-16	BriaCell Therapeutics : Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer	PU
07-16	BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer	AQ
07-15	BriaCell Therapeutics : Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT(TM)	PU
07-15	BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™	AQ
07-07	BriaCell Engages Consulting and Branding Firms to Support Potential Commercialization of Bria-IMT	MT
07-07	BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™	AQ
06-25	BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT	CI
06-25	BriaCell Therapeutics Inks MOU With Dutch Microneedle Company	MT
06-25	BriaCell Therapeutics : Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)	PU
06-25	BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™	AQ
06-09	BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2026	CI
06-02	BriaCell Therapeutics Rises After Hours as It Closes a $4.7-Million Share Offering	MT
06-02	BriaCell Therapeutics Closes $4.7 Million Share Offering	MT
06-02	BriaCell Therapeutics Announces Closing of Offering	AQ
06-01	BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting	MT
06-01	BriaCell Presents Positive Clinical Data at ASCO 2026	AQ
06-01	BriaCell Down 9.3% as Prices Offering to Raise US$4.7 Million	MT
06-01	BriaCell Therapeutics Prices $4.7 Million Share Offering	MT
05-31	Briacell Therapeutics prices 1.45 million common shares at $3.25 per share	RE
05-31	BriaCell Therapeutics Announces Pricing of Offering	AQ
05-26	Briacell Therapeutics Corp. Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study of Bria-Imt Plus Immune Checkpoint Inhibitor in Metastatic Breast Cancer	CI
05-26	BriaCell Receives DSMB Nod to Continue With Phase 3 Metastatic Breast Cancer Study	MT